Literature DB >> 10859147

Metabolism of fluroxypyr, fluroxypyr methyl ester, and the herbicide fluroxypyr methylheptyl ester. I: during percutaneous absorption through fresh rat and human skin in vitro.

P G Hewitt1, J Perkins, S A Hotchkiss.   

Abstract

Percutaneous absorption of pesticides is a major determinant for risk assessment. Furthermore, cutaneous metabolism plays a role in penetration of certain chemicals. Therefore, the aim of these studies was to determine the transdermal metabolism of three related compounds [the herbicide, fluroxypyr methylheptyl ester (FPMH), fluroxypyr methyl ester (FPM), and fluroxypyr (FP)] during penetration through human and rat skin in vitro. The data presented in this article show that both FPM and FPMH were completely metabolized during their passage through human and rat skin in vitro. The only metabolite produced was that of the hydrolysis product, FP, with no parent ester penetrating through the skin. The extent of FP formation within the skin was directly correlated to the degree of stratum corneum reservoir formation. The larger the stratum corneum reservoir, the lower the levels of FP recovered from within the skin. This suggests that as the ester partitioned out of the SC it was immediately hydrolyzed to FP, which could then pass freely through the remainder of the epidermis and dermis. Similar metabolic profiles were observed for the transdermal metabolism of FPM and FPMH in previously frozen rat skin, indicating the robust nature of the esterase enzymes involved. In conclusion, systemic exposure after skin contact with FPM or FPMH is likely to be to the acid metabolite, FP, only and not to the parent ester. In addition, the rate and extent of percutaneous absorption will be a major determinant of cutaneous metabolism.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10859147

Source DB:  PubMed          Journal:  Drug Metab Dispos        ISSN: 0090-9556            Impact factor:   3.922


  8 in total

1.  In vivo and ex vivo percutaneous absorption of [14C]-bisphenol A in rats: a possible extrapolation to human absorption?

Authors:  Fabrice Marquet; Jean-Paul Payan; Dominique Beydon; Ludivine Wathier; Marie-Christine Grandclaude; Elisabeth Ferrari
Journal:  Arch Toxicol       Date:  2011-02-02       Impact factor: 5.153

Review 2.  Xenobiotica-metabolizing enzymes in the skin of rat, mouse, pig, guinea pig, man, and in human skin models.

Authors:  F Oesch; E Fabian; Robert Landsiedel
Journal:  Arch Toxicol       Date:  2018-06-18       Impact factor: 5.153

3.  Human skin permeation of branched-chain 3-0-alkyl ester and carbonate prodrugs of naltrexone.

Authors:  Haranath K Vaddi; Mohamed O Hamad; Jianhong Chen; Stan L Banks; Peter A Crooks; Audra L Stinchcomb
Journal:  Pharm Res       Date:  2005-05-17       Impact factor: 4.200

Review 4.  Xenobiotic-metabolizing enzymes in the skin of rat, mouse, pig, guinea pig, man, and in human skin models.

Authors:  F Oesch; E Fabian; K Guth; R Landsiedel
Journal:  Arch Toxicol       Date:  2014-11-05       Impact factor: 5.153

5.  In vitro/in vivo correlation of transdermal naltrexone prodrugs in hairless guinea pigs.

Authors:  Satyanarayana Valiveti; Kalpana S Paudel; Dana C Hammell; Mohamed O Hamad; Jianhong Chen; Peter A Crooks; Audra L Stinchcomb
Journal:  Pharm Res       Date:  2005-06-08       Impact factor: 4.200

6.  Human skin permeation of 3-O-alkyl carbamate prodrugs of naltrexone.

Authors:  Haranath K Vaddi; Stan L Banks; Jianhong Chen; Dana C Hammell; Peter A Crooks; Audra L Stinchcomb
Journal:  J Pharm Sci       Date:  2009-08       Impact factor: 3.534

7.  In vivo evaluation of a transdermal codrug of 6-beta-naltrexol linked to hydroxybupropion in hairless guinea pigs.

Authors:  Paul K Kiptoo; Kalpana S Paudel; Dana C Hammell; Mohamed O Hamad; Peter A Crooks; Audra L Stinchcomb
Journal:  Eur J Pharm Sci       Date:  2008-01-31       Impact factor: 4.384

8.  Involvement of Carboxylesterase in Hydrolysis of Propranolol Prodrug during Permeation across Rat Skin.

Authors:  Teruko Imai; Yuko Takase; Harunobu Iwase; Mitsuru Hashimoto
Journal:  Pharmaceutics       Date:  2013-07-01       Impact factor: 6.321

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.